Cost Evaluation Analysis of Genetic Testing and Tailored Adjuvant Imatinib in Patients With Resected High-Risk GI Stromal Tumors: The Brazilian Perspective

PURPOSE: Mutations of the KIT gene are the molecular hallmark of most GI stromal tumors (GISTs). Imatinib has revolutionized GIST treatment. Adjuvant imatinib for 3 years is the standard of care for high-risk resected GIST. However, the GIST molecular biologic profile has found different responses t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes David, Bruna Bianca, Nazareth Aguiar Junior, Pedro, Costa e Silva, Matheus, Dienstmann, Rodrigo, Gil Ferreira, Carlos, Serrano, César
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664859/
https://www.ncbi.nlm.nih.gov/pubmed/37856732
http://dx.doi.org/10.1200/GO.23.00070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664859/
https://www.ncbi.nlm.nih.gov/pubmed/37856732
http://dx.doi.org/10.1200/GO.23.00070

Ejemplares similares